NDATOPICALAEROSOL, FOAM
Approved
Oct 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
AMZEEQ (minocycline) by Journey Medical is 12. Approved for acne vulgaris. First approved in 2019.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AMZEEQ is a topical minocycline foam formulation approved in 2019 for acne vulgaris. The mechanism of action and pharmacodynamics remain unknown, though minocycline demonstrates in vitro activity against Propionibacterium acnes with low resistance propensity. The product delivers systemic minocycline exposure with rapid steady-state achievement by Day 6 and minimal accumulation.
$25KPart D
Peak11.3 years to LOEProduct is in peak commercial phase with minimal Part D penetration, indicating limited market adoption or niche positioning within acne treatment.
Mechanism of Action
12.1 Mechanism of Action The mechanism of action of AMZEEQ for the treatment of acne is unknown. 12.2 Pharmacodynamics The pharmacodynamics of AMZEEQ for the treatment of acne are unknown. 12.3 Pharmacokinetics In a pharmacokinetic study, male and female subjects 18 years of age or older with acne…
Indications (1)
Worked on AMZEEQ at Journey Medical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.